TNDM has been the subject of several other research reports. TheStreet downgraded shares of Tandem Diabetes Care from a “c-” rating to a “d+” rating in a report on Monday, June 13th. Bank of America initiated coverage on shares of Tandem Diabetes Care in a report on Wednesday, March 2nd. They set a “neutral” rating and a $130.00 price objective for the company. Piper Sandler decreased their price objective on shares of Tandem Diabetes Care from $170.00 to $120.00 in a report on Thursday, May 5th. Citigroup reduced their target price on shares of Tandem Diabetes Care from $155.00 to $130.00 in a research note on Tuesday, May 17th. Finally, SVB Leerink reiterated a “market perform” rating on shares of Tandem Diabetes Care in a research note on Monday, April 18th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, Tandem Diabetes Care presently has a consensus rating of “Moderate Buy” and a consensus price target of $143.00.
TNDM stock opened at $58.73 on Wednesday. The company has a 50 day simple moving average of $76.70 and a 200 day simple moving average of $106.86. The stock has a market cap of $3.76 billion, a price-to-earnings ratio of 734.22 and a beta of 0.69. Tandem Diabetes Care has a 1 year low of $52.69 and a 1 year high of $155.86. The company has a debt-to-equity ratio of 0.64, a current ratio of 6.21 and a quick ratio of 5.60.
In related news, COO David B. Berger sold 10,097 shares of the company’s stock in a transaction dated Wednesday, June 8th. The shares were sold at an average price of $65.02, for a total value of $656,506.94. Following the transaction, the chief operating officer now owns 2,457 shares in the company, valued at approximately $159,754.14. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO John F. Sheridan purchased 2,500 shares of the company’s stock in a transaction that occurred on Monday, May 9th. The stock was purchased at an average price of $69.90 per share, for a total transaction of $174,750.00. Following the purchase, the chief executive officer now owns 10,058 shares in the company, valued at $703,054.20. The disclosure for this purchase can be found here. Over the last three months, insiders have acquired 5,000 shares of company stock worth $361,270 and have sold 22,607 shares worth $1,829,208. 2.20% of the stock is currently owned by insiders.
A number of institutional investors have recently made changes to their positions in TNDM. Moors & Cabot Inc. bought a new position in Tandem Diabetes Care in the 3rd quarter worth about $25,000. Exane Derivatives bought a new position in Tandem Diabetes Care during the 1st quarter valued at about $33,000. Byrne Asset Management LLC bought a new position in Tandem Diabetes Care during the 4th quarter valued at about $34,000. CI Investments Inc. lifted its stake in Tandem Diabetes Care by 10,566.7% during the 1st quarter. CI Investments Inc. now owns 320 shares of the medical device company’s stock valued at $37,000 after acquiring an additional 317 shares during the period. Finally, Sandy Cove Advisors LLC purchased a new stake in shares of Tandem Diabetes Care during the 1st quarter valued at about $46,000. Institutional investors own 94.62% of the company’s stock.
Tandem Diabetes Care Company Profile (Get Rating)
Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set.
- Get a free copy of the StockNews.com research report on Tandem Diabetes Care (TNDM)
- Zai Lab Stock Has Fallen to Value Levels
- Are These Cheap Copper Stocks Right For Your Portfolio?
- It’s A Comfortable Time To Buy Steelcase
- Worthington Posts Strong Results, But Earnings Fall On One-Off Adjustments
- A Tasty Entry Point Into Darden Restaurants International
Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.